Breast Cancer<sup>18</sup>F-ISO-1 Uptake as a Marker of Proliferation Status

Elizabeth S. McDonald(Hospital of the University of Pennsylvania), David A. Mankoff(University of Pennsylvania), Robert H. Mach(California University of Pennsylvania), Robert K. Doot(University of Pennsylvania), Amy Ziober(University of Pennsylvania), Michael D. Feldman(University of Pennsylvania), Anthony J. Young(University of Pennsylvania), Amy S. Clark(Abramson Center for Jewish Life), Erin K. Schubert(University of Pennsylvania), Michael D. Farwell(University of Pennsylvania), Anupma Nayak(University of Pennsylvania), Daniel A. Pryma(University of Pennsylvania), Hsiaoju Lee(University of Pennsylvania), Angela DeMichele(University of Pennsylvania), Payal D. Shah(Rutgers, The State University of New Jersey), Julia Tchou(University of Pennsylvania)
Journal of Nuclear Medicine
December 13, 2019
10.2967/jnumed.119.232363
Cited by 38

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
|Cell|2017|448
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology
|Neoplasia|2018|446